Submitted : 2025-04-09
Accepted : 2025-04-24
Published : 2025-05-09
Abstract
This document specifies the requirements for institutions and personnel involved in the treatment of osteoarthritis with platelet-rich plasma (PRP), including the acquisition of PRP, the process of local injection therapy, and post-treatment patient examination and follow-up. This document is applicable to the treatment of osteoarthritis patients caused by degenerative diseases in orthopedic and joint surgery departments of general hospitals using PRP.
References
Expert Group of Chinese Guidelines for Diagnosis and Treatment of Osteoarthritis, The Pain Disease Branch of the Chinese Aging Well Association, 2024, Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2024 Edition), https://rs.yiigle.com/cmaid/1512095
The Joint Surgery Branch of the Chinese Orthopedic Association, 2021, Expert Consensus on Clinical Drug Treatment of Osteoarthritis, https://rs.yiigle.com/cmaid/1336682
Expert Group of the Pain Disease Diagnosis and Treatment Special Capacity Training Project of the National Health Commission’s Capacity Building and Continuing Education Center, 2021, Expert Consensus on the Application of Platelet-Rich Plasma in Chronic Musculoskeletal Pain Diseases. Chinese Medical Journal, 101(43): 3528–3533.
China International Exchange and Promotive Association for Medical and Health Care, 2018, Clinical Practice Guidelines for the Treatment of Knee Osteoarthritis with Intra-Articular Injection of Platelet-Rich Plasma. Chinese Journal of Joint Surgery (Electronic Edition), (04): 444–448.